| 1. |
Qi L, Sun M, Liu W, et al. Global esophageal cancer epidemiology in 2022 and predictions for 2050: A comprehensive analysis and projections based on GLOBOCAN data. Chin Med J (Engl), 2024, 137(24): 3108-3116.
|
| 2. |
Yang H, Wang F, Hallemeier CL, et al. Oesophageal cancer. Lancet, 2024, 404(10466): 1991-2005.
|
| 3. |
Kroese TE, Christ SM, van Rossum PSN, et al. Incidence and survival of patients with oligometastatic esophagogastric cancer: A multicenter cohort study. Radiother Oncol, 2022, 173: 269-276.
|
| 4. |
Elliott JA, Markar SR, Klevebro F, et al. An international multicenter study exploring whether surveillance after esophageal cancer surgery impacts oncological and quality of life outcomes (ENSURE). Ann Surg, 2023, 277(5): e1035-e1044.
|
| 5. |
Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol, 1995, 13(1): 8-10.
|
| 6. |
van Hootegem SJM, de Pasqual CA, Giacopuzzi S, et al. Outcomes after surgical treatment of oesophagogastric cancer with synchronous liver metastases: A multicentre retrospective cohort study. Cancers (Basel), 2024, 16(4): 797.
|
| 7. |
Kroese TE, Bronzwaer S, van Rossum PSN, et al. European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4). Eur J Cancer, 2024, 204: 114062.
|
| 8. |
Kroese TE, van Rossum PSN, Nilsson M, et al. Study protocol for the oligometastatic esophagogastric cancer (OMEC) project: A multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer. Eur J Surg Oncol, 2023, 49(1): 21-28.
|
| 9. |
Kroese TE, van Laarhoven HWM, Nilsson M, et al. Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis. Eur J Cancer, 2022, 166: 254-269.
|
| 10. |
Kroese TE, van Hillegersberg R, Schoppmann S et al. Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. Eur J Cancer, 2022, 164: 18-29.
|
| 11. |
Kroese TE, van Laarhoven HWM, Schoppman SF, et al. Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe. Eur J Cancer, 2023, 185: 28-39.
|
| 12. |
Matsumoto C, Iwatsuki M, Morinaga T, et al. The relationship between the treatment course and prognosis of oligometastasis after esophageal squamous cell carcinoma resection. Surg Today, 2024, 54(8): 927-934.
|
| 13. |
Rice TW, Ishwaran H, Hofstetter WL et al. Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus, 2016, 29(8): 897-905.
|
| 14. |
Mine S, Tanaka K, Kawachi H, et al. Japanese classification of esophageal cancer, 12th edition: PartⅠ. Esophagus, 2024, 21(3): 179-215.
|
| 15. |
Liu Q, Chen J, Lin Y, et al. Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): An open-label, randomised, phase 2 trial. Lancet Gastroenterol Hepatol, 2024, 9(1): 45-55.
|
| 16. |
Ichikawa H, Kosugi S, Nakagawa S, et al. Operative treatment for metachronous pulmonary metastasis from esophageal carcinoma. Surg, 2011, 149(2): 164-170.
|
| 17. |
Shiono S, Kawamura M, Sato T, et al. Disease-free interval length correlates to prognosis of patients who underwent metastasectomy for esophageal lung metastases. J Thorac Oncol, 2008, 3(9): 1046-1049.
|
| 18. |
Hamai Y, Hihara J, Emi M, et al. Treatment outcomes and prognostic factors after recurrence of esophageal squamous cell carcinoma. World J Surg, 2018, 42(7): 2190-2198.
|
| 19. |
Ji J, Liu Y, Bao Y, et al. Effects of local treatment in combination with systemic therapy for advanced esophageal cancer: A systematic review and meta-analysis. Adv Radiat Oncol, 2024, 9(7): 101522.
|
| 20. |
Liu Q, Zhu Z, Chen Y, et al. Phase 2 study of stereotactic body radiation therapy for patients with oligometastatic esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys, 2020, 108(3): 707-715.
|
| 21. |
Zhao W, Ke S, Cai X, et al. Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase Ⅱ trial. Radiother Oncol, 2023, 184: 109679.
|
| 22. |
Fujitani K, Yang HK, Mizusawa J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): A phase 3, randomised controlled trial. Lancet Oncol, 2016, 17(3): 309-318.
|
| 23. |
Al-Batran SE, Homann N, Pauligk C, et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: The AIO-FLOT3 Trial. JAMA Oncol, 2017, 3(9): 1237-1244.
|
| 24. |
Liu C, Tsai PC, Chien LI, et al. Esophagectomy in patients with esophageal squamous cell carcinoma and distant nodal metastasis. Dis Esophagus, 2024, 37(11): doae064.
|
| 25. |
Igaue S, Nozaki R, Utsunomiya D, et al. Significance of surgery for resectable m1 lymph node metastases without organ metastasis in esophageal carcinoma in the era of neoadjuvant treatment. Ann Surg Oncol, 2024, 31(3): 1525-1535.
|
| 26. |
Hingorani M, Stubley H. Oligometastatic esophageal cancer cured by systemic therapy combined with radiotherapy to primary tumor and metastasis (metastasis-directed therapy)-small case series. Explor Target Antitumor Ther, 2024, 5(4): 921-930.
|
| 27. |
Yamaguchi H, Fukumitsu N, Numajiri H, et al. The Japanese nationwide cohort data of proton beam therapy for liver oligometastasis in esophagogastric cancer patients. J Radiat Res, 2023, 64(6): 926-932.
|
| 28. |
Yamaguchi H, Kato T, Honda M, et al. Proton beam therapy for lung oligometastatic recurrence in patients with esophageal cancer. Cureus, 2023, 15(12): e50343.
|
| 29. |
Li J, Wen Y, Xiang Z, et al. Radical radiotherapy for metachronous oligometastasis after initial treatment of esophageal cancer. Radiother Oncol, 2021, 154: 201-206.
|
| 30. |
Ohkura Y, Shindoh J, Ueno M, et al. Clinicopathologic characteristics of oligometastases from esophageal cancer and long-term outcomes of resection. Ann Surg Oncol, 2020, 27(3): 651-659.
|
| 31. |
Chen Y, Cheng X, Song H, et al. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for esophageal squamous cell cancer patients presenting with oligometastases. J Thorac Dis, 2019, 11(4): 1536-1545.
|
| 32. |
Duan Y, Qin W, Yang L, et al. Safety and efficacy of concurrent or sequential radiotherapy plus (pd-1) inhibitors in oligometastatic esophageal cancer. Cancer Manag Res, 2023, 15: 55-65.
|
| 33. |
Qin J, Xue L, Hao A, et al. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: The randomized phase 3 ESCORT-NEO/NCCES01 trial. Nat Med, 2024, 30(9): 2549-2557.
|
